We are saddened to learn of the tragic death of Nicholas Kelly, aged 16, due to a suspected allergic reaction, and would like to offer our deepest sympathies to his family at this difficult time. We have very little detail
Read more
4th March 2020 The UK’s regulator of medicines (Medicines & Healthcare products Regulatory Agency [MHRA]) has received updated information from the company that makes Emerade pens about the defect previously reported by the MHRA. The defect means some pens may
Read more
Developing new guidance for healthcare professionals looking after teenagers and young adults with allergies and/or asthma. It is important that young people learn how to self-manage their allergies and/or asthma. Adolescence can be a challenging time for them and their
Read more
The Food Standards Agency (FSA) are inviting those affected or interested in food hypersensitivity to participate in an online survey and share their experiences. Around 2% of adults and 8% of children in the UK have a food hypersensitivity. This
Read more
The Anaphylaxis Campaign has received the following updated statement from Mylan regarding the availability of EpiPen. This includes information for patients, prescribers, pharmacists, hospitals and schools. Mylan’s manufacturing partner Meridian Medical Technologies, a subsidiary of Pfizer that manufactures EpiPen®, has
Read more
The Anaphylaxis Campaign is saddened to learn of the death of Sam Collings, aged 19, who died at Bolton Hospital on the 4th August 2019. According to media reports, neither Sam or his family had suspected that Sam suffered from
Read more
The Anaphylaxis Campaign is delighted to hear about the success of Aimmune Therapeutics, Inc. in the approval of their oral immunotherapy drug, Palforzia, by the US Food and Drug Administration (FDA). This is the first oral immunotherapy drug that has
Read more
An editorial in the February edition of Clinical and Experimental Allergy (the official journal of the British Society of Allergy and Clinical Immunology) explores the current statutory guidance on the care of children with medical conditions in schools, and highlights
Read more
Biopharmaceutical company DBV Technologies has announced positive results from its Viaskin® Peanut trial into reducing the risk of allergic reaction in children aged 4 to 11. Viaskin is a patch applied directly to the surface of the skin and contains
Read more